RE: May's start22 May 2024 13:42
Mad, SA does intend to present towards the end of Jun; see his comment on a recent response to a couple of questions I raised and he kindly answered
Stuart,
First of all thankyou for the very full and positive presentation on the Investor Meets platform.
I have a couple of questions regarding the demarcation between the 5 Pillars, for instance we were informed by Greg that the Dermatonics Once Heel Balm is prescribed as a treatment by over 4500 GPs and Specialists so why is it only categorised in the Medical pillar rather than the Pharma Pillar as well and where would it sit if you were to separately list the Companies and why?
The boundaries between the Skinbiotix (Cosmetic) and Medical pillars are equally blurred. Whilst I appreciate that as an ingredient because of its many properties it can straddle all the pillars depending on its use, when it is used as a cosmetic to reduce wrinkles surely with the clinical evidence behind it, it is only the concentration of this active ingredient in a Customers final product that will determine whether it is medical (recommended by a specialist) or cosmetic? Assuming my assumption to be true, then as the current agreement with Croda is for cosmetic use only, and in some instances they supply the ingredient only and have no control over the concentration and which "premium products" their Customers use it in, wont you need to extend the terms of the agreement to include medical use?
Thanks in anticipation of a response
Firstly, please accept my apologies for the delayed response, your original message appears to have been filtered for some reason or other, this occasionally happens with mail from Hotmail addresses.
In answer to your questions please see below:
1. At this moment in time the Dermatonics once heel balm sits within the medical device pillar but does potentially hold a place within the pharmaceutical pillar. Products like this are often difficult to pigeonhole. The pillar approach was launched four years ago and, as with all strategies, we must remain somewhat flexible. In some countries the product is sold over the counter and this is where the blurring occurs. Were we to list the pillars individually we would need to have some form of end point carve out. We are monitoring endpoint purchase at present and will adjust accordingly.
2. This one is rather tricky, you are correct in your assumption that the lysate can be used in both cosmetic and medical applications. The Croda agreement relates very specifically to one sector of application, active skincare in the cosmetic field. Our agreement allows access to the finished product to then sell into the medical device space. This does not require an amendment to the agreement with Croda.
I will be updating the market as to recent progress before the end of June as per my commitment to deliver six presentations each year. We have conducted two IMC meetings thus far this year and are due another before end of Q2.
Many t
Sign In
Follow the stocks
